Expression of the double or triple mutants of RUNX2 in breast cancer cells reduces the mRNA levels of two metastasis-related target genes, MMP9 and MMP13, and reduces the RUNX2-dependent invasive potential of breast cancer cells. Here, RUNX2 is linked to breast carcinoma.